Amneal Pharmaceuticals (AMRX) return on equity (ROE)

Return on equity · fiscal 2023
-424.6%

Amneal Pharmaceuticals (AMRX) earned a return on equity of -424.6% in fiscal 2023 (the year ended December 31, 2023). That is 381.1 percentage points lower than the -43.6% of fiscal 2022. Figures as of 17 Nov 2026, 22:02 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2023
-424.6%
Change on fiscal 2022
−381.1 pts
Highest on record
22.4%fiscal 2020
Lowest on record
-424.6%fiscal 2023
Fiscal years on record
62018–2023

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Amneal Pharmaceuticals return on equity (ROE), in more detail

Across the 6 fiscal years on record (2018–2023), the highest was 22.4% in fiscal 2020 and the lowest -424.6% in fiscal 2023. The fiscal 2023 figure is no higher than in any of the 5 earlier fiscal years on record, whose median is -3.9%.

History · 6 fiscal years

Return on equity by fiscal year

Amneal Pharmaceuticals return on equity (ROE), year by year

Amneal Pharmaceuticals (AMRX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2023-424.6% 381.1 pts down
2022-43.6% 47.2 pts down
20213.7% 18.7 pts down
202022.4% 282.5 pts up
2019-260.1% 256.2 pts down
2018-3.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Amneal Pharmaceuticals and comparable companies
CompanyReturn on equityFiscal year
Cytokinetics CYTK-88.3%2021
ABIVAX ABVX-73.8%2025
Bausch + Lomb BLCO-5.6%2025
Amneal Pharmaceuticals AMRX-424.6%2023
Caris Life Sciences CAI-11.8%2025
Immunovant IMVT-59.3%2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AMRX

Amneal Pharmaceuticals, figure by figure

Amneal Pharmaceuticals (AMRX) overview: price, valuation and scorecardAll health care companies by market value

Amneal Pharmaceuticals return on equity (ROE): questions and answers

What is Amneal Pharmaceuticals's return on equity?

Amneal Pharmaceuticals (AMRX) earned a return on equity of -424.6% in fiscal 2023 (the year ended December 31, 2023). That is 381.1 percentage points lower than the -43.6% of fiscal 2022.

Is Amneal Pharmaceuticals's return on equity high or low compared with its own history?

The fiscal 2023 figure is no higher than in any of the 5 earlier fiscal years on record, whose median is -3.9%.

What are the highest and lowest return on equity figures on record for Amneal Pharmaceuticals?

Across the 6 fiscal years on record (2018–2023), the highest was 22.4% in fiscal 2020 and the lowest -424.6% in fiscal 2023.

How is Amneal Pharmaceuticals's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Amneal Pharmaceuticals (AMRX) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/AMRX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.